Diya O, Gayed J, Lowry FS, Ma H, et al. A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults >/=18 years old. Vaccine 2025;52:126869.
PMID: 39999538